Fresh analysis suggests that people who stop using popular slimming jabs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise programs.
Research printed in a prominent medical journal shows that while obese people frequently drop substantial amounts of their body weight while using the jabs, the weight is regained at an average rate of nearly a kilo each month upon discontinuation.
"Users purchasing such drugs should be informed of the potential of quick rebound weight gain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain suggests a reversion to starting mass in about a year and a half.
Weighing Therapies
The study, which examined dozens of trials involving thousands of participants, compared the outcomes of the injectable medications with other pills.
Researchers note that individuals who lose weight through dieting generally see a less rapid creep back—around 100 grams monthly—post-intervention.
The Reason for the Rapid Rebound
Experts propose the way of the jabs is key to understanding the amplified weight return.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of GLP-1 levels several times higher than normal may cause the body to produce less of its endogenous hormone, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication means appetite is unsuppressed, making overeating much more probable."
A Chronic Disease?
Health authorities suggest the injections for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
Many experts say that, given the significant potential of relapse, the therapy might need to be life-long.
This view is echoed by drug manufacturers, who state that the findings "emphasize the persistent character of excess weight," comparing it to managing diseases like diabetes.
User Testimonies
Users who have stopped the medication explain a sudden return of hunger.
"It was like something flipping and you become ravenous," said one woman.
The struggle is worsened if individuals have not established lasting dietary or behavioural changes during therapy.
Significant Use
Survey data indicate that a significant number of adults in the UK have used these injections in the last 12 months, with demand being substantial.
- Adoption is more common among females than males.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Ultimately, researchers caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a permanent solution and maintained weight loss hinges on ongoing behavioural support.
